Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shingrix in varicella‑naive renal transplant recipients
2019-002529-31Phase 4Terminated
- Sponsor
- Oslo University Hospital
- Start
- Dec 2019
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of Zoster vaccine recombinant in Varicella zoster infection (2 arms), sponsored by Oslo University Hospital. Primary endpoints: Seroconversion at 6 months after last dose and Seroconversion at 12 months after last dose. Started Dec 2019; status: terminated.
02
Drugs
Zoster vaccine recombinant
03
Conditions
Varicella zoster infection
Beyond the preview
Go deeper on 2019-002529-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002529-31.